EcoDrugPlus

Proteasome 20s Subunit Alpha 7

Ensembl ID : ENSBMUG00000023856
Gene Symbol: PSMA7
2 Cross references
150 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSBMUG00000016299
Gene Symbol: PSMA8
3 Cross references
198 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSBMUG00000026197
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSBMUG00000002931
Gene Symbol: PSMB10
3 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSBMUG00000021571
Gene Symbol: PSMB2
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSBMUG00000001393
Gene Symbol: PSMB3
3 Cross references
251 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSBMUG00000024466
Gene Symbol: PSMB4
3 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSBMUG00000018220
Gene Symbol: PSMB5
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSBMUG00000005111
Gene Symbol: PSMB6
3 Cross references
209 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSBMUG00000020516
Gene Symbol: PSMB7
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSBMUG00000007942
Gene Symbol: PSMB8
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSBMUG00000007982
Gene Symbol: PSMB9
3 Cross references
214 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).